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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYCardiomyocytes from human embryonic stem cells (hESC-CMs) and induced pluripotent stem cells (hiPSC-CMs) represent newmodels
for drug discovery. Although hypertrophy is a high-priority target, we found that hiPSC-CMs were systematically unresponsive to hyper-
trophic signals such as the a-adrenoceptor (aAR) agonist phenylephrine (PE) compared to hESC-CMs. We investigated signaling at
multiple levels to understand the underlying mechanism of this differential responsiveness. The expression of the normal a1AR gene,
ADRA1A, was reversibly silenced during differentiation, accompanied by ADRA1B upregulation in either cell type. ADRA1B signaling
was intact in hESC-CMs, but not in hiPSC-CMs. We observed an increased tonic activity of inhibitory kinase pathways in hiPSC-CMs,
and inhibition of antihypertrophic kinases revealed hypertrophic increases. There is tonic suppression of cell growth in hiPSC-CMs,
but not hESC-CMs, limiting their use in investigation of hypertrophic signaling. These data raise questions regarding the hiPSC-CM
as a valid model for certain aspects of cardiac disease.INTRODUCTION
The potential of stem cell-derived cardiomyocytes for
disease modeling has been enhanced by the realization
that cardiomyocytes from human embryonic stem cells
(hESC-CMs) and induced pluripotent stem cells (hiPSC-
CMs) can be obtained also with disease-specific genotypes
and phenotypes (Park et al., 2008). These cells are suggested
to have many of the properties of authentic cardiomyo-
cytes, and their phenotypes provide validation that charac-
teristics of the disease can be reproduced in vitro (Park
et al., 2008). The initial focus for using hESC-CMs or
hiPSC-CMs was modeling acute cardiac responses, with
the aim of producing models of contractile impairment,
contractile frequency, or arrhythmias or for using cells as
a screen to identify cardiotoxicity of experimental or clin-
ical compounds. An important goal is now to extend this
to modeling of longer-term disease processes. Hypertrophy
is an obvious target for investigation, given its central role
in the transition to heart failure. Intense studies in animal
models and human myocardium have revealed hypertro-
phic networks with complex interdependence and redun-
dancies (Ryall et al., 2012), which makes the design of
therapies challenging. The high-throughput capabilities
of the hESC-CM/hiPSC-CM system are ideally placed to
dissect these pathway interactions by systems approachesStem Cell Rand then to translate into a drug discovery platform. Our
earlier data have revealed the ability of hESC-CMs to
respond to canonical pathological and physiological hy-
pertrophic stimuli (Fo¨ldes et al., 2011). In the present study,
we extend these observations using newly designed assays
on a number of automated platforms and show how these
approaches can identify new targets. Although the field
of modeling of genetic diseases has advanced rapidly,
researchers have started to evaluate more critically hiPSCs
relative to hESCs (Ma et al., 2014) and have made an effort
to better understand how these cell populations differ
from one another. We present here data showing that
hiPSC-CMs diverge systematically from hESC-CMs and
investigate the reason for the difference at multiple levels
from receptor expression to kinase effector pathways.RESULTS
Distinct Responses of Cardiomyocyte Derived from
hESC and hiPSC Lines to Phenylephrine
The structural features of 30- to 40-day-old hESC-CMs and
hiPSC-CMs (details of cell lines are in Table S1 available on-
line) were analyzed and compared using immunocyto-
chemistry. Cardiomyocytes differentiated from various
hESCs in different laboratories or companies (H7, Imperialeports j Vol. 3 j 905–914 j November 11, 2014 j ª2014 The Authors 905
Figure 1. Distinct Responses of Cardio-
myocyte Derived from hESC and hiPSC
Lines to Phenylephrine
(A) Representative immunofluorescence
confocal image and 3D rendering of a
confocal image stack showing differenti-
ated hiPSC-CMs stained positive for cardiac-
specific myosin heavy chain a/b (green)
and ANF (red) at 30 days after differentia-
tion. Nuclei are stained with DAPI (blue).
White scale bars represent 20 mm. Car-
diomyocytes differentiated from various
hESC (H7, HUES7, and SHEF3) and hiPSC
(LQT2, LQT2-PAT, CDI, and ReproCell) lines
showed comparable morphology after
plating onto 0.5% gelatine. The hESC-CMs
and hiPSC-CMs were treated with phenyl-
ephrine (PE) (10 mM, 48 hr) at 30 days after
differentiation.
(B and C) Bar graphs showing fold change in
2D cell area (B) and ANF mRNA levels (C) in
cells treated with pPE. Results are shown
as fold changes versus control group. n >
100 MHC-positive cells analyzed per well
(mean ± SEM), from two to ten biological
replicates. *p < 0.05, ***p < 0.001 versus
control groups; Student’s t test.
See also Figures S1 and S2.
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Aberrant aAR Hypertrophy Response in hiPSC-CMsCollege and GE Healthcare; HUES7, University of Notting-
ham; and SHEF3, UK Stem Cell Bank) and hiPSCs (hiPSCs
reprogrammed from HUES7 hESC-derived fibroblasts,
LQT2, and LQT2-PAT, University of Nottingham; iCell,
Cellular Dynamics; and ReproCell) lines showed compara-
ble morphology after plating onto 0.5% gelatine (represen-
tative cell images in Figure 1A). Specifically, hiPSC-CMs
and hESC-CMs displayed structural features of the imma-
ture phenotype in terms of shape and sarcomeric pattern
(Gherghiceanu et al., 2011). We investigated the effects of
hypertrophic stimuli on cell area of various hESC-CM and
hiPSC-CM types. Administration of phenylephrine (PE) re-
sulted in a significant increase in cell area of hESC-CMs
(H7: 1.4-fold, p < 0.05; SHEF3: 1.5-fold, p < 0.05; HUES7:
2.8-fold, p < 0.001 versus control; Figure 1B). In contrast,
administration of PE did not change the myosin heavy
chain (MHC)-labeled 2D area of hiPSC-CMs from any of
the stem cell lines (LQT2, LQT2-PAT, iCell, and ReproCell
hiPSC-CMs; Figure 1B). Furthermore, mRNA levels of
ANF, a marker of hypertrophy, increased in various hESC-
CMs while staying unchanged in hiPSC-CMs (Figure 1C).
Similarly, there were no significant changes in BNP
mRNA levels in response to PE (0.75 ± 0.15 as compared
with control, p = 0.29, n = 3). Given the known hypertro-
phic effect of serum on primary rat neonatal cells, and
the reported effect on hESC-CMs/hiPSC-CMs (Dambrot906 Stem Cell Reports j Vol. 3 j 905–914 j November 11, 2014 j ª2014 Theet al., 2014), we compared the hESC-CMs (H7) and
hiPSC-CMs (iCell) with 20% serum or no serum in the me-
dium (RPMI/B27). High-content analyses of these did not
reveal any significant differences in hypertrophic respon-
siveness (Figure S1).
Responses to Other Hypertrophic Agonists
Endothelin-1 increased mRNA levels of ANF both in hESC-
CMs and hiPSC-CMs after 24 hr (p < 0.01), while the
increase in cell size was small (10%, not significant) (Fig-
ure S2). Angiotensin II had no significant effect on hESC-
CM and hiPSC-CM cell size and increased ANF mRNA
levels only in hESC-CMs (Figure S2). Endothelin-1 at
10 nM concentration increased BNP mRNA levels in
hiPSC-CMs (2.42 ± 0.16-fold, n = 3, p = 0.038) whereas
angiotensin II had no effect (0.97 ± 0.12, p = 0.81, n = 3).
Administration of b-adrenergic agonist isoprenaline
(10mM) alone or in combination with b1AR inhibitor
CGP20712A (300 nM) to reveal b2AR effects had minimal
effect on cell size in hESC-CMs or hiPSC-CMs (Figures
S2E–S2G), although contractile responses to b1AR or b2AR
agonists were intact.
Loss of ADRA1A Expression during Differentiation
Our data confirmed ADRA1A as the main a-adrenergic re-
ceptor isoform in adult ventricular cardiomyocytes, whileAuthors
Figure 2. Silenced Expression of ADRA1A
during hESC and hiPSC Differentiation
toward Cardiomyocyte
(A) Bar graphs showing mRNA levels of
ADRA1A in undifferentiated hESC, hiPSC,
hiPSC-CM, hESC-CM, as well as adult my-
ocytes and fetal heart and fibroblasts.
(B) Line graph showing the time course of
ADRA1A downregulation during differenti-
ation of H7 hESC by serum-free directed
differentiation and serum-based EB
methods (mean ± SEM; four biological rep-
licates; ***p < 0.001 versus control groups;
one-way ANOVA with Dunnett’s post hoc
test).
(C–E) Diagram showing the experimental
scheme of differentiation and reprogram-
ming. Bar graphs showing ADRA1A mRNA
(C), OCT4 mRNA (D), and ADRA1A pre-mRNA
levels (E) in HUES7-hESC, HUES7-hiPSC, and
HUES7-hiPSC-derived cardiomyocytes or fi-
broblasts, adult skin fibroblasts, and hiPSC-
and hiPSC-derived cardiomyocytes from a
patient with LQT2 syndrome and a healthy
relative (LQT2-PAT).
Undifferentiated cells are shown as
gray, differentiated cardiomyocytes as
red, differentiated fibroblasts as blue, adult
cardiomyocytes as dark red, and adult
fibroblasts as dark blue bars. Results are
shown as fold changes versus the undiffer-
entiated hESC group (H7 in A and B; HUES7
in C–E, respectively); mean ± SEM. Samples
were measured in triplicate from two bio-
logical replicates. See also Figure S3.
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Aberrant aAR Hypertrophy Response in hiPSC-CMsexpression was much lower for ADRA1B (Figures 2A and
S3A). Human fetal fibroblasts, adult heart samples, as well
as isolated adult ventricular myocytes showed abundant
expression of ADRA1A, suggesting a preserved dominant
expression of ADRA1A during human cardiogenesis (Fig-
ure 2A). ADRA1A mRNA was present in undifferentiated
hESCs and hiPSCs (although modest compared with adult
cells) but was not detectable in differentiated hiPSC-CMs or
hESC-CMs (Figure 2A). Prior exposure to hypertrophic ef-
fectors such as PE or endothelin-1 did not induce ADRA1A
mRNA expression in hiPSC-CMs.Stem Cell RExpression of ADRA1A mRNA was markedly down-
regulated during differentiation from all hESC and
hiPSC lines we studied (Figure 2A). Downregulation
was independent from reprogramming methods of
hiPSC or differentiation methods (Table S1; Figure 2A).
Downregulation of ADRA1A mRNA was rapid (following
an early transient upregulation in ADRA1A within
2–4 hr) and was stable, as shown by long-term
follow-up of differentiated hESC-CM cultures made by
either the embryoid body or Activin A/BMP4 methods
(Figure 2B).eports j Vol. 3 j 905–914 j November 11, 2014 j ª2014 The Authors 907
Figure 3. Upregulation of ADRA1B
Expression during Differentiation of
hESCs and hiPSCs
(A) Quantitative RT-PCR data on ADRA1B
expressions in undifferentiated hESCs,
hiPSCs, hiPSC-CMs, hESC-CMs, and adult
myocytes isolated from the left ventricle,
adult heart, and fetal heart and fibro-
blasts. Undifferentiated cells are shown
as gray, differentiated cardiomyocytes as
red, differentiated fibroblasts as blue,
adult cardiomyocytes as dark red, and
adult fibroblasts as dark blue bars. Data
are expressed as relative changes versus
DMSO-treated differentiating control
hESCs or hiPSCs; mean ± SEM, ***p <
0.001 versus undifferentiated group; Student’s t test. Samples are from three biological replicates.
(B) The diagram in Figure 2 shows the experimental scheme of differentiation and reprogramming. Bar graphs showing ADRA1B mRNA in
HUES7-hESC-, HUES7-hiPSC-, and HUES7-hiPSC-derived cardiomyocytes or fibroblasts, adult skin fibroblasts, and hiPSC- and hiPSC-derived
cardiomyocytes from a patient with LQT2 syndrome and a healthy relative (LQT2-PAT) are presented. Undifferentiated cells are shown as
gray, differentiated cardiomyocytes as red, differentiated fibroblasts as blue, adult cardiomyocytes as dark red, and adult fibroblasts as
dark blue bars. Results are shown as fold changes versus undifferentiated hESC group; mean ± SEM. Samples were measured in triplicate
from two biological replicates.
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Aberrant aAR Hypertrophy Response in hiPSC-CMsReprogramming of adult fibroblasts with low or no
ADRA1A mRNA levels resulted in a considerable increase
in ADRA1AmRNA levels in the undifferentiated state (Fig-
ure 2C) from arrhythmic patients with long QT2 syn-
drome or a healthy relative (LQT2-PAT). During further
differentiation of the patient-derived hiPSC lines into
beating cardiomyocytes, there was a silencing of ADRA1A
expression. In both cases, ADRA1A levels changed in par-
allel with the undifferentiated pluripotent stem marker
OCT4 (Figure 2D). To further compare hESC-CMs with
hiPSC-CMs in a robust system, we have also used
HUES7 hESC line as a starting point (with measurable
ADRA1A mRNA levels; Figure 2C). Differentiation of
HUES7 hESCs into fibroblasts and cardiomyocytes re-
sulted in a loss of ADRA1A mRNA expression. Then, we
reprogrammed HUES7-derived fibroblasts into hiPSCs
(HUES7-hiPSCs), which restored ADRA1A mRNA expres-
sion. Finally, further differentiation of HUES7-hiPSCs
into cardiomyocyte cultures switched off ADRA1A expres-
sion (Figure 2C). Again, changes in mRNA levels of marker
OCT4 were parallel to those of ADR1A in all samples
(Figure 2D). We measured changes in pre-mRNA levels
of ADRA1A by intron-specific real-time PCR primers to
reflect changes in gene transcription rates in addition to
measurements of mRNA levels by exonic probes (Fig-
ure 2E). Changes in pre-mRNA levels were parallel with
exon-specific profile, suggesting that these together may
mainly reflect changes in ADRA1A gene transcription
rate in the differentiated cardiomyocytes and pluripotent
stem cells (Ponzio et al., 2007).908 Stem Cell Reports j Vol. 3 j 905–914 j November 11, 2014 j ª2014 TheCoregulation of the a1B-Adrenergic Receptor
Since the a1ARwas lost in both hESC-CMs and hiPSC-CMs,
this left the question of why the hESC-CMs were still able
to respond to PE. It is known that there are other subtypes
of the a1AR, and that a1BAR can also support the hypertro-
phic response (O’Connell et al., 2003). In contrast to
ADRA1A, expression of ADRA1B showed marked upregula-
tion during differentiation of hESCs or hiPSCs toward car-
diomyocytes (and fibroblasts), bringing expression levels
to those of adult cells (Figure 3A). This was reversible by
reprogramming fibroblasts into undifferentiated hiPSCs
(Figure 3B) (Ponzio et al., 2007).
Rescue of ADRA1A Did Not Restore
Responsiveness to PE
WeoverexpressedADRA1A in hiPSC-CMs, resulting 10,000-
fold increase inADRA1A expression, reaching a comparable
level to those in adult cardiomyocytes (Figures 4A and 4B).
ADRA1Awas widely spread, with an apparent strong locali-
zation onmicrotubule network as well as close to themem-
brane and nucleus (Figure 4A). However, cell size and atrial
natriuretic factor (ANF) mRNA levels did not change in
response to PE in hiPSC-CMs with high ADRA1A levels
(Figures 4C and 4D), suggesting changes in downstream
signaling were additionally preventing hypertrophy.
Distinct Expression of Downstream G Proteins during
Differentiation
Downstream partners of adrenergic signaling including
Gq, Gb1, and Gg2 proteins were all detectable in variousAuthors
Figure 4. Overexpression of ADRA1A in hiPSC-CM
(A) Localization of ADRA1A in hiPSC-CM (iCell) transfected with
ADRA1A-eYFP construct. White scale bar represents 20 mm.
(B–D) Bar graphs showing ADRA1A mRNA levels (B), cell size (C),
and ANF mRNA levels (D) in hiPSC-CMs transfected with ADRA1A
without or in the presence of PE after 48 hr; mean ± SEM; six
biological replicates. ***p < 0.001 versus control group; one-way
ANOVA with Tukey’s post hoc test.
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fibroblasts, and adult ventricular cardiomyocytes (Figures
5A–5C). Our data show an increase in Gq, Gb1, and
Gg2 mRNA levels during cardiac differentiation in
hESC differentiation. In contrast, in most differentiating
hiPSC lines, mRNA levels of Gq, Gb1, and Gg2 were un-
changed or downregulated during differentiation, suggest-
ing a distinct regulation of downstream signaling elements
(Figures 5D–5F).
Distinct a1BAR-Adrenergic Receptor-Dependent
Kinase Pathways in hESC-CMs and hiPSC-CMs
We assessed downstream signaling pathways using prote-
ome screening for kinase phosphorylation. Despite the
lack of functional responses in hypertrophy-related param-
eters, evidence of active signaling was seen in hiPSC-CMs,Stem Cell Ras well as the expected effects in hESC-CMs. Phosphoryla-
tion of src family members Lck (Y394), Yes (Y426), Fgr
(Y412), Chk2 (T68), and Pyk2 (Y402) was markedly
increased in response to PE after 48 hr in both cell types
(Figure 6A). In some aspects, hiPSC-CMs were more
affected than hESC-CMs; there was activation of STAT3
(Y705), STAT5a/b (Y694/699), and STAT6 (Y641) as well
as of b-catenin and GSK3a/b (S21/59) and GSK3b/Wnt-
pathway elements, while phosphorylation levels of these
kinases were unchanged or decreased in hESC-CMs in
response to PE (Figure 6A). For RSK, Pyk2, P70 S6, and
p27, the opposite pattern was seen, with increased phos-
phoprotein in hESC-CMs but unchanged or decreased
phosphoprotein in hiPSC-CMs. Connections between the
kinases were explored by Ingenuity Pathway Analysis,
and a schematic diagram showed how STAT3, which
is an established ADRA1B downstream target (Han et al.,
2008), could produce the phosphorylation changes
observed in an EGFRK/Src/GSK3b network (Figure 6B).
Inducing Cell Growth in hiPSC-CMs by Kinase
Inhibition/Activation
Our previous study had identified protein kinase pathways
(mTOR and ERK1/2) that regulate PE-induced changes cell
area and ANF expression in hESC-CMs (Fo¨ldes et al., 2011),
and this was confirmed here (Figure 6C). Here we used
these methods for a comparison between hESC-CM and
hiPSC-CM, with newly developed assays for 2D and 3D
automated microscopy and an extended library of inhibi-
tors. Unexpectedly, given the lack of increase in cell area
with PE in hiPSC-CMs, the same kinase inhibitors
decreased cell area in those cells also (Figure 6C). This sug-
gests that these pathways are active inmaintaining cell size
in both cell types, but theremay be additionalmechanisms
in hiPSC-CMs that are producing a tonic suppression of the
hypertrophic response to PE. Given the implication that
ADRA1B might stimulate hypertrophy through a STAT3
cascade, inhibitors and activators of STAT3 were tested in
hESC-CMs and hiPSC-CMs. STAT3 inhibitor VIII, 5,15-
DPP was able to block PE-induced increase in cell size of
hESC-CMs as well as decrease basal cell size in both cell
types. We observed a similar tendency with cell-permeable
STAT3 inhibitor protein. However, STAT3 inhibitor protein
had no effect on hiPSC-CMs (iCell, from CDI) (Figures S4A
and S4B). Conversely, the STAT3 agonist interleukin-6
(IL-6), while ineffective alone, rescued a strongly hypertro-
phic effect of PE on cell area in hiPSC-CM (Figures 6D–6F).
Interestingly, translocation assays of STAT3 to the nu-
cleus showed the movement to be induced by PE alone,
which had no hypertrophic effect, as well PE + IL-6, which
did, further supporting the idea of active hypertrophic
signaling by PE in hiPSC-CMs suppressed by additional
pathways (Figure 6E). To investigate this further, we usedeports j Vol. 3 j 905–914 j November 11, 2014 j ª2014 The Authors 909
Figure 5. Distinct Expressions of Downstream G Protein during Differentiation from hESCs and hiPSCs toward hESC-CMs and
hiPSC-CMs
(A–C) mRNA for Gq (A), Gb1 (B), and Gg2 (C) proteins were all detectable in various lines of undifferentiated hESC (light gray bars) and
hiPSC (dark gray bars) cultures, fetal hearts, and fibroblasts and adult ventricular cardiomyocytes from heart failure patients (black bars).
Results are shown as fold changes versus the undifferentiated hESC (HUES7) group (mean ± SEM; three biological replicates).
(D–F) Changes in mRNA levels for Gq (D), Gb1 (E), and Gg2 (F) during differentiation of hESCs of hiPSCs are also presented. Results are
shown as fold changes versus the respective undifferentiated hESC or hiPSC line. Samples were measured in triplicate from three biological
replicates. *p < 0.05, ***p < 0.001; Student’s t test.
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phoproteome network above (Figure 6B). GSK3b and (in
some cases) EGFRKhad different effects between PE-treated
hESC-CMs and hiPSC-CMs in the control of cell area (Fig-
ure 6C), volume (Figures S5A and S5B), sarcomere organiza-
tion (Figures S5A and S5C) and/or ANF subcellular distribu-
tion (Figures S5A and S5D). Simultaneously targeting these
kinases with a combination of GSK3b, EGFRK, and CAMKII
inhibitors had an inducer effect on cell growth (Figure 6G).DISCUSSION
a-Adrenergic receptors play a critical role in the regulation
of cellular growth pathways, including hypertrophy and
proliferation. G protein-coupled a1ARs are the predomi-
nant a-adrenergic subtype in the myocardium of most spe-
cies (Bru¨ckner et al., 1985), and catecholamine receptor
agonists strongly induce pathological cardiac hypertrophy
both in vivo and in vitro (Zhong and Minneman, 1999;
Rokosh et al., 1996). Development of model systems have910 Stem Cell Reports j Vol. 3 j 905–914 j November 11, 2014 j ª2014 Thetherefore focused on the response through the a1AR as a
means to understand the downstream signaling involved
and to develop therapeutic agents against hypertrophic
conditions. Expression ofADRA1A subtypemRNAs is tissue
and cell specific (Stewart et al., 1994), and control of
ADRA1mRNAs by agonists can be also diverse in different
cells (Rokosh et al., 1996). It is therefore crucial that the
new hESC-CMs and hiPSC-CMs are characterized with
respect to their a1AR repertoire. We had previously seen
robust and specific effects of the canonical a1AR agonist
PE on a wide range of markers of hypertrophy such as cell
size, cell volume, ANF expression, sarcomere alignment,
and protein/DNA ratio (Fo¨ldes et al., 2011).While these ob-
servations were confirmed here in an hESC-CM from a
number of lines, surprisingly we found that hiPSC-CM
were in contrast unresponsive to PE. Loss of PE response
was independent from the cell line, cell culture conditions,
reprogramming, and differentiating protocols we used and
was reproduced in different laboratories.
Our data confirm that a1AAR (ADRA1A gene) is the
dominant receptor subtype of the a1AR expressed in theAuthors
Figure 6. Phosphokinase Proteome and
Kinase Inhibitor Analyses of PE-Induced
Signaling in hESC-CMs and hiPSC-CMs
(A) Relative changes in phosphoprotein
levels in response to PE (10 mM, 48 hr) in
hESC-CMs (H7) and hiPSC-CMs (iCell).
(B) Schematic diagram of Ingenuity
Pathway Analysis-mapped mechanistic in-
teractions of active epidermal growth factor
receptor kinase, STAT family members, and
GSK3b/ b-catenin and Src kinase pathways.
Arrows between nodes represent direct
(solid lines) and indirect (dashed lines)
interactions between molecules as sup-
ported by information in the Ingenuity
Pathway Knowledge Base.
(C) Assessment of kinase inhibitors on hy-
pertrophy. Human ESC-CMs (H7) and hiPSC-
CMs (iCell and ReproCell) were treated
with PE in the presence of kinase in-
hibitors. Bar graphs show changes in
response to selected kinase inhibitors on
cell area by automated high-content mi-
croscopy. Robust Z score was computed and
visualized.
(D–F) Representative image and quantita-
tion of nuclear translocation of STAT3
(D and E) and cell area (F) in hiPSC-CMs
treated with PE in the presence of inter-
leukin-6 (100 ng/ml) in hiPSC-CMs. White
scale bar represents 20 mm.
(G) Cell area in hiPSC-CMs treated with PE
in the presence of combined inhibition of
GSK3b/EGFRK/CAMKII/src/PDGFRK (1 mM
each); mean ± SEM; four biological repli-
cates; one-way ANOVA with Tukey’s post
hoc test.
See also Figures S4 and S5.
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Aberrant aAR Hypertrophy Response in hiPSC-CMshuman adult heart and ventricular myocytes. However,
cardiomyocytes differentiated from hESCs or hiPSCs did
not measurably express the ADRA1A gene. ADRA1A
mRNA was expressed (albeit modestly) in undifferentiated
hESCs and hiPSCs but disappeared rapidly during differ-
entiation to either cardiomyocytes or fibroblasts. There
was a close correspondence between loss of pluripotency
genes and loss of the ADRA1A receptor. Once again, thisStem Cell Rwas independent of line or reprogramming method; in
our definitive experiment, we showed this by reprogram-
ming fibroblasts differentiated from an hESC line and
comparing the resulting hiPSC-CMs with the hESC-CMs
from the same line. Since loss of the a1AAR occurred in
both hESC-CMs and hiPSC-CMs, we were now left with
the conundrum of why there was an active PE response
in hESC-CMs and why the two cell types differed. Weeports j Vol. 3 j 905–914 j November 11, 2014 j ª2014 The Authors 911
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Aberrant aAR Hypertrophy Response in hiPSC-CMsfurther explored alternate aAR subtypes and showed that
differentiation activated a unique, nonontogenetic gene
program by a marked shift from ADRA1A toward a
dominant ADRA1B subtype both in hiPSC-CMs and
hESC-CMs. However, expression levels of ADRA1B were
considerably increased in both cell types, which again
did not explain the difference between hiPSC-CMs and
hESC-CMs. Other subtypes (ADRA1D or ADRA2C) are
also present both in hiPSC-CMs and hESC-CMs. However,
lack of hypertrophic responsiveness to PE suggests that
their presence is not sufficient to mediate PE effects in
hiPSC-CMs.
We then attempted to restore the response to PE by over-
expression of ADRA1A, but this too was unsuccessful
despite high levels of receptor expression. This strongly
suggests that there is either loss of coupling components
for the downstream signaling pathway or active repression
of hypertrophy by opposing signaling pathways. The next
level of regulation for the a1AR is at the G protein-
coupling stage, with agonist binding to the receptor allow-
ing activation of the Gaq subunit by dissociation from
Gbg proteins. While levels of Gaq, Gb, and Gg were
similar between undifferentiated hESCs and hiPSCs (and
also similar to adult cardiomyocytes), differences then
occurred during differentiation. We found an increase in
Gq, Gb1, and Gg2 mRNA levels during hESC differentia-
tion, whereas in most differentiating hiPSC lines, the
mRNA levels were unchanged or downregulated. This rep-
resents a clear difference between the two cell types and
would be expected to produce a relative damping of the
hypertrophic response in hiPSC-CMs. However, other
Gq-coupled hypertrophic agents (ET-1 and angiotensin
II) produced only small changes in cell size in either cell
type, but robust increases in ANF and B-type natriuretic
peptide (BNP) were observed even in hiPSC-CMs. This sug-
gests that G protein coupling is not entirely compromised
in these cells. Increases in cell size somewhat larger than
this have been reported for iCell hiPSC-CMs with ET-1
(24% versus our 10%) (Carlson et al., 2013), but it is
notable that the stronger BNP signal was chosen for the
final hypertrophy assay in that study, which would be
consistent with our findings.
We next used the high-content imaging to further define
hypertrophic pathway interactions in hESC-CMs and
hiPSC-CMs and to compare this with data defining the
phosphorylation effects of PE treatment. We have devel-
oped 2D and 3D imaging processes to analyze hypertrophic
phenotype of our cells using high-content analysis, and we
used these while extending our original panel of kinase in-
hibitors (Fo¨ldes et al., 2011) to cover many pivotal kinase
targets. This is an important advance on our previous ex-
periments, where we used a limited panel, because few in-
hibitors are completely specific. In Figures 6C and S5, the912 Stem Cell Reports j Vol. 3 j 905–914 j November 11, 2014 j ª2014 Theabscissa titles show that many inhibitors havemultiple tar-
gets; bioinformatic analysis was therefore necessary to de-
convolve the pathways clusters involved. Although the
positive effect of PE on hypertrophic markers was not
evident in hiPSC-CMs, we were surprised to see negative ef-
fects of kinase inhibitors on a number of parameters. These
included the original p38-MAPK, ERK1/2, and mTOR in-
hibitors that were effective in hESC-CMs (in both this
and our previous study; Fo¨ldes et al., 2011). Some inhibi-
tors, such as those for GSK3b and EGFRK, were also able
to increase cell size and area, suggesting that there had
been tonic suppression of cell growth by these pathways.
We also noted a number of clear differences between
hESC-CM and hiPSC-CM responses, such as an increase
of cell volume in hiPSC-CMs, but not hESC-CMs, with in-
hibitors of EGFRK or the STATactivator JAK-2. This suggests
a greater tonic suppression of ADRA1B hypertrophic
signaling in the hiPSC-CM, which would again contribute
to the poor responses to PE.
Detection of PE-dependent phosphorylation of the ki-
nases themselves with a proteome profiling array showed
that Src family kinases, a nonreceptor tyrosine kinase group
implicated in controlling G protein-coupled receptor traf-
ficking and effects on cell proliferation and cytoskeletal
rearrangement, were markedly activated in hESC-CMs
and hiPSC-CMs. The Ingenuity Pathway Analysis identi-
fied an EGFR/Src/GSK3b/STAT3 network modulated by
ADRA1B that could drive the hypertrophic process.
STAT3 is an established ADRA1B downstream target (Han
et al., 2008), and the finding is in line with previous reports
of activation of Src-dependent pathways by ADRA1 and
crosstalk between EGF signaling and ADRA1 in cardiac hy-
pertrophy (Li et al., 2011; Zitron et al., 2008; Asakura et al.,
2002). Supporting this schema, a STAT3 inhibitor was able
to reduce both basal and PE-stimulated cell area in the
hESC-CMs as well as basal in hiPSC-CMs. Also, a STAT acti-
vator (IL-6) caused a marked increase in PE-stimulated cell
area in the hiPSC-CMs. PE was able to induce STAT3 move-
ment to the nucleus, but it was only able to increase cell
area in the presence of IL-6. The simultaneous activation
of EGFRK/GSK3b by PE via STAT3 may have restrained
the final cell size change following translocation. A smaller
panel of inhibitors, based on the array above, was used
in combination to identify the antihypertrophic pathways
most active in the hiPSC-CMs. This confirmed the EGFRK/
GSK3b combination, together with CamKII, as optimal to
increase cell area.
We conclude that the main difference in hiPSC-CMs
that accounts for the defective response to a1AR stimula-
tion is the suppression of growth by tonic antihypertro-
phic pathways (Figure 7), including EGFRK, GSK3b, and
CamKII. The limitations of this study are that this screen
is not fully comprehensive, and so we may have missedAuthors
Figure 7. Schematic Summary of Poten-
tial Differences in Adrenergic Receptor-
Driven Regulation of Cell Growth and
Hypertrophy in hiPSC-CMs and hESC-CMs
Red is used to represent active/upregulated
components and gray for relatively inactive
or downregulated components.
Stem Cell Reports
Aberrant aAR Hypertrophy Response in hiPSC-CMsother elements and combinations that could have further
rescued hypertrophy in hiPSC-CMs. Nor can we say that
this will be predictive of every hiPSC-CM line, since we
have not identified the genetic or epigenetic change pro-
duced by the reprogramming process, which may have
triggered the different balancing of hypertrophic/antihy-
pertrophic pathways. We further note that even in hESC-
CMs, where a1AR-mediated cell size increases are clear,
there has been a differentiation-induced shift in the aAR
subtype. These data send an important message that
superficial similarities in phenotype between cardiomyo-
cytes derived from hESCs or hiPSCs, and parallels to
adult cardiomyocytes, may mask complex differences in
signaling. This has implications for their use in drug dis-
covery, where targets identified using pluripotent stem
cell derivative may not ultimately act in the same way in
adult human cardiac cells.EXPERIMENTAL PROCEDURES
Human Pluripotent Stem Cell-Derived
Cardiomyocytes
Cardiomyocytes derived from hESC and hiPSC lines were gener-
ated from dense monolayers with Activin A and bone morphoge-
netic protein 4 (BMP4) or by using the embryoid body (EB)
differentiating system. Protocols for hiPSC reprogramming
and cardiomyocyte differentiation of each line are summarized
in Table S1.
Use of Hypertrophic Stimuli
In vitro assays and cell lines to analyze hypertrophic responsive-
ness are listed in Table S2. To determine the effect of hypertro-
phic G protein-coupled receptor agonist, after incubation
for 1 hr, plates were treated with the prohypertrophic a-adreno-
ceptor agonist PE (10 mM, Sigma) or vehicle for 48 hr. For
iCell hiPSC-CMs and H7 hESC-CMs, the experiments were
repeated in serum-free medium and in the presence of 20% fetalStem Cell Rbovine serum (Dambrot et al., 2014). In a separate set of experi-
ments, cells were also treated with angiotensin II (Sigma;
100 nM), the b-adrenergic agonist isoprenaline (Sigma; 10 mM)
with or without selective beta1 blocker CGP20712A (Sigma;
300 nM) for 48 hr, or endothelin1 (Sigma; 1, 10, and 100 nM)
for 24 hr.
High-Content Imaging for Hypertrophy Assessment
We have developed high-content immunocytochemistry assays to
characterize hypertrophic properties of hESC-CMs and hiPSC-CMs
in culture. Cells were scanned on ArrayScan VTi 2D automated
microscopy (Cellomics) and a confocal Opera LX plate reader
(PerkinElmer).
Real-Time PCR for G Protein-Coupled Receptors and
Downstream Signaling
Real-time PCR analyses were performed with TaqMan Gene
Expression Assays on samples from undifferentiated and differen-
tiated hESC and hiPSC cultures, adult isolated myocytes, and fetal
heart and fibroblast.
Kinase Inhibitor Screen
Using BioMol Screen-Well Kinase Inhibitor Library, we assessed the
role of protein kinases on basal and PE-induced changes in hyper-
trophy readouts.
Phosphokinase Assay
hESC-CMs and hiPSC-CMs were seeded in six-well plates and
treated with PE (10 mM) for 48 hr. Screening for different phospho-
kinases in cell lysates was performedwith a human phosphokinase
antibody array (R&D Systems). Pathway analysis was performed by
Ingenuity Pathway Analysis.
Statistical Analysis
Results are expressed as mean ± SEM. The data were analyzed by
unpaired Student’s t test or one-way analysis of variance and
Tukey’s post hoc test for multiple comparisons. Differences at
the level of p < 0.05 were considered statistically significant.eports j Vol. 3 j 905–914 j November 11, 2014 j ª2014 The Authors 913
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